Key Drivers
- Profitability Surge
- Leverage Increase
- Strong Liquidity
AIAI Summary
ADMA has shifted from a turnaround biotech to a profitable, cash-generating ASCENIV-led business, but the stock now depends on continued high-growth execution while litigation, product concentration, and rising debt threaten to cap the valuation if credibility slips.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Profitability Surge
- •Leverage Increase
- •Strong Liquidity
ADMA remains highly profitable and cash-generative with strong liquidity, but rising leverage, weaker debt coverage, and a still-stretched valuation temper the investment case.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •Resistance cap
- •Support floor
ADMA remains in a constructive uptrend over the last month, but the pullback from $10.06 shows it needs to clear $9.90-$10.06 to extend higher while holding $8.70-$8.80 support.
Sharp run to $10.06 followed by a pullback to $9.41, signaling active overhead selling
Sentiment & News
Key News Insights:
- •ASCENIV Growth
- •Margin Expansion
- •Legal Overhang
ADMA showed solid 2Q growth led by ASCENIV and improving margins, but ongoing securities-fraud litigation and governance allegations are likely to keep sentiment pressured.
The stock may react positively to stronger operating execution, but litigation risk remains a major drag on multiple and investor confidence
Similar Companies in Healthcare
Other companies in the same sector with AI ratings